ZaZa Energy , ZAZA, Profile, Summary
ZaZa Energy , ZAZA, Profile, Summary
ZaZa Energy Overview
CONSOLIDATING A DOMINANT POSITION IN THE EAGLEBINE
>High concentration of liquid rich assets in the Eaglebine and Eagle Ford trends
> ~110,000 acre presence within the Eaglebine and Lower Cretaceous window
> 7,600 acres surrounded by Devon’s recently acquired $6 billion GeoSouthern Eagle Ford assets
> Completed amendment to Eaglebine/Eagle Ford East joint venture agreement with large independent operator
> Accelerated timing
> Contiguous JV acreage footprint
> Immediate liquidity (~$17.8MM net cash) and production (~$17MM in PDP value)
> 6 well carry program
> Proven management team
> Significant experience with majors and large independents
> Collectively participated in the drilling and completion of over 5,500 wells
UNCONVENTIONAL ASSETS – POST CONVENTIONAL THINKING
MILESTONES - POSITIONED FOR RAPID VALUE CREATION-
> Secured a first mover advantage in the Eaglebine/Eagle Ford East play
> Consummated joint venture agreement with a large independent operator to develop Eaglebine/Eagle Ford East acreage
> Accelerated original joint venture agreement through an amendment to acquire additional production and further develop our acreage block
> Entered joint venture agreement with Sabine Oil & Gas LLC, a First Reserve portfolio company, to develop Sweet Home Eagle Ford acreage
> Strategically completed sale of non core Moulton Eagle Ford assets for approximately $38 million
> Reduced senior secured notes to $26.8 million from $100 million
> Drilled and completed 4 proof?of?concept wells during 2013
EAGLE FORD SHALE PROPERTIES
JOIN VENTURE
SWEET HOMEPROSPECT
PROVEN BUSINESS MODEL
Initial Appraisal
Proof of Concept
Capital Markets Access
Proven Management Team
Todd Brooks (Founder, Executive Director, President &
CEO)
Ian Fay (CFO)
Kevin Schepel (EVP Exploration and Production)
Thomas Bowman (EVP Evaluation, Geology and Geophysics)
The Advantage
Approach
Results
Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ
Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®
Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
If you want to get your company profiled or have questions/comments, please don't hesitate to contact the Editor [@] OxBridgeResearch.com
The Alkaline Water Company, WTER, Profile
The Alkaline Water Company | WTER | Profile
The Alkaline Water Company employs a state-of-the-art Electrochemically Activated Water (ECA) system to create 8.8 pH drinking water without the use of any chemicals. The ECA process uses specialized electronic cells coated with a variety of rare earth minerals to produce scientifically engineered water.The Company further incorporate 84 trace Himalayan minerals considered to be the best in the world.
Waternomics
-
A typical American drinks about 10 cases of bottled water a year.
-
In 2011, total bottled water sales in the U.S. hit 9.1 billion gallons — 29.2 gallons of bottled water per person, according to sales figures from Beverage Marketing Corp.
-
The 2011 numbers are the highest total volume of bottled water ever sold in the U.S., and also the highest per-person volume.
-
Bottled water sales aren’t just growing —they’re booming. Volume increased by 4.1 percent in 2011 —five times as fast as the 0.9 percent growth in the sales of beverages overall, according to Beverage Marketing. Bottled water sales, in fact, are growing twice as fast as the economy itself.
-
The U.S Market is predicted to double in in the next two years.
Water is the new front:
Old Rivals Pepsi & Coke fighting for market share
-
The three global giants in the industry Coca Cola and Pepsi and Nestle
-
Pepsi’s Aquafina, introduced in 1997, is now the number one branded non-carbonated bottled water in the US.
-
Coke’s Dasani, launched a few months later, is second in the category. Both are likely to lead the market in the future.
-
Market analysts look for major consolidation among the plethora of brands in the next few years.
-
It is anticipated that large national marketers will buy local brands around the country and shut them down. Why? To reduce competition and, in some cases, to acquire other supply sources for spring water.
-
The battle between Coke and Pepsi and the larger European brands is the “high profile war that will be waged,” predicts at least one industry insider, who adds that branding will remain a deciding factor for discerning consumers. “Quality and trust are going to be critical, so brands will be important.”
The Opportunity
Virtually no competitive products sized larger than 1.5 L in the market.
-
Consumer acceptance for Alkaline water continues to grow significantly due to its many perceived health benefits, making it the water of choice.
-
Bulk Alkaline water can be marketed at a consumer price point significantly less, per ounce, than existing brands.
-
There is a high demand amongst major retailers for bulk alkaline waters.
-
New bulk size option well received by existing consumers of alkaline water.
Sources: The company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ
Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®
Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
If you want to get your company profiled or have questions/comments, please don't hesitate to contact the Editor [@] OxBridgeResearch.com
Hemispherx Biopharma, HEB, Profile, Summary
Hemispherx Biopharma, HEB, Profile, Summary
Hemispherx Biopharma, HEB, is a biopharmaceutical company dedicated to treating and preventing chronic viral and immune-based disorders through the development and manufacturing of compounds that enhance the natural immune system of the human body. Hemispherx Biopharma, has developed over nearly three decades a vast body of knowledge relating to a potentially new class of pharmaceutical products (nucleic acid compounds) that are designed to activate otherwise dormant cellular defenses against viruses and tumors.
The Company’s flagship products include Alferon N Injection® and the experimental immunotherapeutics Ampligen®. Its platform technology includes large and small agents for potential treatment of various chronic viral infections.
Ampligen®, is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted at such important diseases as Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), HIV, Hepatitis B, Hepatitis C, and cancers including kidney cancer and metastatic malignant melanoma.
Alferon N Injection® (interferon alfa-n3, human leukocyte derived) is a highly purified, natural source, glycosylated, multi-species alpha interferon product, composed of eight forms of high-purified alpha interferon. It is the only natural source, multi-species alfa interferon currently sold in the United States and is also approved for sale Argentina. Alferon N Injection® is the company’s registered trademark for it’s injectible formulation or natural alpha interferon approved by the FDA for the treatment of genital HPV (refractory condylomata acuminata). Alferon N Injection® may also have activity against other viral infections such as Multiple Sclerosis, Hepatitis C, HIV, West Nile Virus, and SARS, but has not been approved for that use.
Ampligen®
Ampligen®, the company's lead compound addresses a variety of chronic diseases and viral disorders. Ampligen® drugs for several viral disorders are under development. More than 40,000 doses at over 20 U.S. clinical trial sites have been delivered with Ampligen®.
ALFERON N Injection®
ALFERON N Injection® [Interferon alfa-n3 (human leukocyte derived)] is the Company's registered trademark for its injectable formulation of Natural Alpha Interferon, approved by the U.S. Food and Drug Administration (FDA) for the intralesional treatment of refractory or recurring external condylomata acuminata in patients 18 years of age or older.
ALFERON N Injection® is the only highly purified, natural-source, multispecies alpha interferon product currently sold in the U.S. and is also approved for sale in Argentina.
Clinically Effective:
-
All warts disappeared in 54% of patients.3
-
No recurrence in 76% of complete responders at follow-up.3
-
Completely cleared 73% of all treated warts.3,4
-
No human antibodies to interferon alfa-n3 detected in clinical trails.3,4
-
Provides a spectrum of multiple alpha interferon subtypes.1,2
Well-tolerated
-
No surgery or caustics and resultant ulceration or scarring.
-
No specific post-treatment care necessary.4
-
The most common adverse effects (mild to moderate, transient flu-like symptoms) were comparable to placebo after 304 weeks of therapy.3.4
-
The majority of patients considered Alferon N Injection preferable to conventional therapy. 3.4
Please see the package insert for prescribing information.
Alferon Low Dose Oral (LDO)®
Alferon LDO®, Hemispherx's oral form of Our Anferon N product (Low Dose Oral Interferon Alfa-N3, Human Leukocyte Derived), which is a new delivery form of our FDA approved drug, Alferon N® is the only natural interferon currently FDA approved and available in the marketplace. Hemispherx has initiated clinical trials as part of an accelerated evaluation of the experimental bio-therapeutic Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) as a potential new experimental therapy for Avian Flu and other lethal viral diseases, which have high acute death rates. Clinical trials in human volunteers (being conducted in both the U.S. at Drexel University, Philadelphia, and shortly to commence in Hong Kong at the Princess Margaret Hospital) are designed to determine whether Alferon N, delivered in a new, experimental oral drug delivery format, can resuscitate the broad-spectrum antiviral and immunostimulatory genes. These human genes are shut down by acute lethal viral infections such as avian flu and smallpox
Sources: The Company, OxBridge Research, Daily Stock Deals, Penny Stock Monster, OTC King
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
If you want to get your company profiled or have questions/comments, please don't hesitate to contact the Editor [@ ] OxBridgeResearch.com
HPV, HIV, Chronic Fatigue Syndrome (CFS), Hepatitis, influenza, H5N1, H7N9, avian influenza, drug resistant avian influenza, Hepatitis A, viral, bacterial, viral infections, Multiple Sclerosis, Hepatitis C, West Nile Virus, SARS, FDA. CIDC.
Immnuocellular, IMUC, Profile, Summary
Immnuocellular Therapeutics | IMUC | Profile | Summary
ImmunoCellular Therapeutics is developing immune-based therapies for the treatment of brain cancer and other tumors. Our lead product candidate, ICT-107, is a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma multiforme (GBM), the most common and lethal type of brain cancer. Our pipeline also includes ICT-121, a dendritic cell (DC) vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells.
ImmunoCellular Therapeutics aims to become an industry-leading, independent, commercial-stage cancer immunotherapy company serving patients in major markets.
ImmunoCellular Cancer Vaccine Manufacturing Process
Each of ImmunoCellular’s dendritic cell (DC) vaccines is prepared from blood collected from each patient. The process, which takes only a few days to complete, is designed to generate sufficient cryopreserved (frozen) cells for dosing through the induction and maintenance phases of immunotherapy. Our GMP manufacturing process adheres strictly to standard operating procedures to ensure consistency, quality and sterility.
The process begins with an apheresis (also referred to as leukapheresis), a common procedure in which the patient’s blood is circulated through a machine to collect the white blood cells.
ImmunoCellular Therapeutics’ proprietary cancer vaccine immunotherapy technology has the potential to transform the treatment of cancer by improving survival and offering safer and more effective treatments than conventional cancer therapies. Our dendritic cell (DC)-based immunotherapies are designed to target both tumor cells as well as cancer stem cells by utilizing multiple tumor-specific antigens to trigger a powerful antitumor immune system response. Utilizing an advanced manufacturing process, we can produce multiple doses from a single apheresis, and offer the advantages of potency, versatility, efficiency, cost-effectiveness and convenience compared to earlier generation cancer vaccines.
Our dendritic cell (DC) vaccine technology and advanced manufacturing offer several advantages over earlier-generation cellular immunotherapies:
-
Potency
-
Matured DCs secrete IL12, which is critical for stimulating T cell killing of cancer cells.
-
More than 80% of the final manufactured product consists of matured DCs.
-
-
Versatility
-
Unlike other cell-based vaccines, our DCs target multiple antigens, thus increasing the likelihood of effective treatment.
-
-
Efficiency
-
Advanced manufacturing enables production of at least 20 doses of vaccine from a single apheresis (blood collection); thus patients do not need to undergo additional apheresis procedures.
-
-
Cost-effectiveness
-
Compared to the only approved cell-based immunotherapy, our DC vaccines can be manufactured at a significantly reduced cost.
-
-
Convenience
-
Ability to freeze and store vaccine for months or years eliminates the need to administer to the patient shortly after manufacture.
-
Intradermal administration route reduces the time and inconvenience of intravenous infusion for both patient and physician.
-
Source: IMUC, OxBridge Research, Daily Stock Deal, OTCking
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
Disclaimer/Disclosure: we receive compensation from companies we feature on our websites/blogs/emails/newsletters or comment on social media/FB/TWTR etc. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
- Petro River Oil, PTRC, Profile, Summary
- OxBridge Research initiates coverage of Teryl Resources,TRC.V, with a price target of 14 cents
- GenVec, GNVC, Profile, Summary
- Teryl Resources, TRC.V/TRYLF, Profile
- Velti, VELT, Profile, Summary
- Anavex Life Sciences, AVXL, Profile, Summary
- FFFC, Fast Funds Financial, Profile, Life Collateralized Mortgage Obligagtion
Feed Entries
